Clinical Trial

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-01-04.
Trial Details
NCT Number NCT05195294
Lead Sponsor Lion TCR Pte. Ltd.
Conditions Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
Enrollment 55 participants
Start Date 2025-03
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-10